Shenyang Xingqi Pharmaceutical Co.,Ltd

Shenzhen Stock Exchange 300573.SZ

Shenyang Xingqi Pharmaceutical Co.,Ltd Revenue for the year ending December 31, 2023: USD 206.71 M

Shenyang Xingqi Pharmaceutical Co.,Ltd Revenue is USD 206.71 M for the year ending December 31, 2023, a 14.13% change year over year. Revenue is the total amount of money generated from the sales of goods or services by a company during a specific period.

Shenyang Xingqi Pharmaceutical Co.,Ltd Revenue for the year ending December 31, 2022 was USD 181.12 M, a 11.96% change year over year.
Shenyang Xingqi Pharmaceutical Co.,Ltd Revenue for the year ending December 31, 2021 was USD 161.77 M, a 53.33% change year over year.
Shenyang Xingqi Pharmaceutical Co.,Ltd Revenue for the year ending December 31, 2020 was USD 105.51 M, a 35.45% change year over year.
Shenyang Xingqi Pharmaceutical Co.,Ltd Revenue for the year ending December 31, 2019 was USD 77.89 M, a 24.24% change year over year.

Key data

Date	Revenue	Gross Profit	Operating Income	EBIT

Shenzhen Stock Exchange: 300573.SZ

Shenyang Xingqi Pharmaceutical Co.,Ltd

CEO	Ms. E. Gao
IPO Date	Dec. 9, 2016
Location	China
Headquarters	No. 68, Lishui Street
Employees	1,995
Sector	Health Care
Industries Pharmaceuticals Cosmetics Eyewear

Description

Shenyang Xingqi Pharmaceutical Co., Ltd engages in the research and development, production, and sale of ophthalmic products in China. It offers corneal, anti-bacteria, artificial tears, anti-inflammation, surgical perfusate, mydriactics, anti-fatigue, and pre dry and over dry eye treatment products. The company is based in Shenyang, China.

Key trends

Past 5 years